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ABSTRACT 
Background:  Resveratrol,  a  plant  polyphenol  existing  in  grapes  and  many  other  natural 
foods, possesses a wide range of biological activities including cancer prevention. It has been 
recognized that resveratrol is intracellularly biotransformed to different metabolites, but no 
direct evidence has been available to ascertain its bioactive form because of the difficulty to 
maintain resveratrol unmetabolized in vivo or in vitro. It would be therefore worthwhile to 
elucidate the potential therapeutic implications  of resveratrol  metabolism  using a  reliable 
resveratrol-sensitive cancer cells. 
 
Objective: To identify the real biological form of trans-resveratrol and to evaluate the safety 
of the effective anticancer dose of resveratrol for the normal brain cells. 
 
Methods: The samples were prepared from the condition media and cell lysates of human 
glioblastoma U251 cells, and were purified by solid phase extraction (SPE). The samples 
were  subjected  to  high  performance  liquid  chromatography  (HPLC)  and  liquid 
chromatography/tandem mass spectrometry (LC/MS) analysis. According to the metabolite(s), 
trans-resveratrol was biotransformed in vitro by the method described elsewhere, and the 
resulting  solution  was  used  to  treat  U251  cells.  Meanwhile,  the  responses  of  U251  and 
primarily cultured rat normal brain cells (glial cells and neurons) to 100μM trans-resveratrol 
were evaluated by multiple experimental methods. Functional Foods in Health and Disease 2013; 3(5):146-153                    Page 147 of 153 
 
Results: The results revealed that resveratrol monosulfate was the major metabolite in U251 
cells.  About  half  fraction  of  resveratrol  monosulfate  was  prepared  in  vitro  and  this 
trans-resveratrol and resveratrol monosulfate mixture showed little inhibitory effect on U251 
cells. It is also found that rat primary brain cells (PBCs) not only resist 100μM but also 
tolerate as high as 200μM resveratrol treatment.   
 
Conclusions: Our study thus demonstrated that trans-resveratrol was the bioactive form in 
glioblastoma cells and, therefore, the biotransforming activity of trans-resveratrol would be 
reversely correlated with the chemosensitivity of the treated cells. The findings from PBCs 
suggest that an effective anti-glioblastoma dose of resveratrol may not exert side-effect on 
normal  brain  cells,  providing  a  strong  evidence  for  practical  use  of  resveratrol  in  the 
management of human brain malignancies.   
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BACKGROUND:   
Glioblastoma multiforme (GM) is the most common primary brain malignancy in human 
adults  [1].  Irrespective  to  the  combination  of  surgical  operation  with  improved  external 
radiotherapy and adjuvant chemotherapy, the prognosis of GMB remains very poor due to its 
highly aggressive biological behavior and frequent recurrence rate [2]. Therefore, exploring 
effective and less toxic chemotherapeutic approaches would be of clinical values in better 
management of this sort of lethal disease.   
Resveratrol,  a plant polyphenol  existing in  grapes  and many other natural  foods [3], 
possesses  a  wide  range  of  biological  activities  including  cancer  prevention  [4,5].  More 
importantly, resveratrol has little cytotoxic effect and is able to penetrate blood-brain barrier 
[6], suggesting its potential therapeutic values in the management of glioblastoma. It has been 
recognized that resveratrol is intracellularly biotransformed to different metabolites, but no 
direct evidence has been available to ascertain its bioactivity form, and how normal brain 
cells respond to this agent. So it would be worthwhile to identify the real biological form of 
trans-resveratrol and evaluate the resveratrol’s safety in the normal glial cells with effective 
anticancer dose. 
 
MATERIALS AND METHODS: 
Primary rat brain cell culture and treatment. A 1-day-old Wistar rats were obtained from 
the Experimental Animals Center of Dalian Medical University. The rat brains were freshly 
removed and minced with a scalpel and triturated in high glucose DMEM (Gibico, Invitrogen 
Corporation, NY, USA). After centrifugation at 2000 rpm for 5 minutes, the brain cells were 
washed with DMEM and centrifugated for 5 minutes. The cell suspensions were plated to 
60mm  dishes  (Nunc  A/S,  Rosklide,  Denmark)  and  cultured  in  high  glucose  DMEM Functional Foods in Health and Disease 2013; 3(5):146-153                    Page 148 of 153 
supplemented with 10% FBS under 37
oC and 5% CO2 condition, then treated with resveratrol. 
All  experimental  protocols  had  been  reviewed  and  approved  by  the  ethics  committee  of 
Dalian  Medical  University  (ECDMU-09066)  for  protection  of  human  subjects  and 
experimental animals before conducting the project. 
 
Sample preparation and purification. After 100μM resveratrol treatment, the primary brain 
cells and glioblastoma U251 cells were collected, washed three times with PBS (pH 7.4), and 
lysed  by  sonication.  Meanwhile,  cell-free  media  were  harvested  directly  by  the  end  of 
48-hour resveratrol treatment or after an additional 24-hour normal culture. The collected 
media and cell lysates were centrifuged at 10,000g for 5 minutes, and the supernatants were 
purified  by  SPE  [7].  The  eluate  was  dried  by  nitrogen  spraying,  and  the  residues  were 
dissolved in 500μL methanol and a 10μL aliquot was injected onto the liquid chromatography 
column for HPLC and LC/MS analysis. 
 
Structural  identification  of  resveratrol  metabolite(s).  The  HPLC  system  (Waters  Co., 
Milford, MA, USA) is consisted of a Waters 1525 binary pump and 2487 dual wavelength 
UV-VIS detector. The detection was carried out at 306nm [8]. Chromatographic separation of 
resveratrol and its metabolite(s) was performed on a  Cosmosil 5C18-AR-Ⅱ  column (4.6 
ID×250  mm,  NACALAI  TESQUE,  INC.  Japan)  containing  a  C18  guard  column  (5μm, 
4.6×10mm), using the mobile phase of 5mM ammonium acetate (phase A) and methanol 
(phase B) with a flow rate of 1.0 ml/min. The gradient solution conditions were referred 
elsewhere  [9].  Further  LC-MS/MS  analysis  was  performed  on  a  Agilent  1200  liquid 
chromatography series (Agilent Technol Inc., Santa Clara, CA, USA) coupled to an Applied 
Biosystems API 3200 QTrap tandem mass spectrometer (Applied Biosystem/MDS SCIEX, 
Foster  City,  CA,  USA)  equipped  with  an  ESI  source,  and  operated  by  Applied 
Biosystem/MDS SCIEX analyst software (Version 1.4.1) to obtain the MS and MS/MS data 
in a negative ion mode [9]. Further identification and confirmation of the metabolites was 
performed  on  a  Shimadzu  LC/MS-IT-TOF  (Shimadzu  Co.,  Kyoto,  Japan)  instrument 
equipped with an ESI source in negative ion mode at a resolution of 10000 FWHM. MS data 
were processed with LC/MS solution ver. 3.4 software (Shimadzu, Japan). 
 
Resveratrol  biotransformation  and  cell  treatment.  One  female  specific  pathogen  free 
Wistar rat was cultured in a wire cage in a room maintained at 22°C with a 12-hour light/dark 
period at the Experimental Animal Center of Dalian Medical University. It was sacrificed by 
an  animal  expert  in  accordance  with  approved  Ministerial  procedures  appropriate  to  the 
species.  The  brain  tissue  was  rapidly  obtained  and  treated  to  prepare  cytosolic 
sulfotransferase.   
For resveratrol sulfonation, 5mM resveratrol, 100μL cytosolic sulfotransferase, 2mM 
PAPS (Sigma Chem Co., St. Louis, MO, USA), 1mM DTT and 20mM Mops buffer were 
admixed and incubated at 37°C for 2h. After the product was centrifuged, the supernatant 
was subjected to HPLC and LC/MS analysis, and the aliquots of the remaining part were used Functional Foods in Health and Disease 2013; 3(5):146-153                    Page 149 of 153 
to treat U251 cells in the total concentration of 100μM. The cells treated by the chemical 
solution for brain lysate preparation, the brain lysate alone and the combination of resveratrol 
and  brain  lysate  (without  PAPS  supplementation)  were  respectively  used  as  background 
controls. 
 
RESULTS: 
Resveratrol monosulfate as major metabolite. According to the HPLC and LC-MS/MS 
analysis, the major metabolite in human glioblastoma U251 cells was resveratrol monosulfate 
Figure  1A.  The  [M-H]
-  ion  of  the  compound  (tR=12.92min)  showed  the  deprotonated 
molecule ions of m/z 307 and 227, respectively, and the ion corresponding to resveratrol (m/z 
227) through the neutral loss of the sulfate unit (m/z 80) from the resveratrol monosulfate, 
then the m/z 227 was fragmented to m/z 185 for the further loss of 42 amu (C2H2O) from 
resveratrol (Figure 1B), which was concluded to resveratrol monosulfate as reported by other 
investigators [10]. The compound was further confirmed by HRMS that gave the [M-H]
- 
molecular  ion  exact  mass  as  307.0261  (C14H11SO6,  calculated  m/z  307.0276),  which 
corresponded to resveratrol monosulfate.   
Figure 1. LC-MS analyses of resveratrol metabolites in glioblastoma U251 cells   
(A) HPLC-UV chromatography analysis on the metabolites of U251 cells treated with 100μM resveratrol for 
48h. 1, 2 represent trans-resveratrol and cis-resveratrol, respectively. (B) indicates the MS1 and MS2 analysis of 
the metabolite of resveratrol. ? represents resveratrol monosulfate. Functional Foods in Health and Disease 2013; 3(5):146-153                    Page 150 of 153 
Metabolic pattern of resveratrol in glioblastoma cells. Furthermore, the results showed 
that the resveratrol monosulfate concentration increased to the platform level at 12-hour time 
point, but the U251 cells reached apoptotic peak at 48-hour time point, which suggested that 
the  metabolic  mechanism  pre-existed  in  the  tumor  cells  apoptosis  and  its  efficiency  was 
enhanced  in  response  to  resveratrol  treatment.  It  was  also  noticed  that  the  amounts  of 
trans-resveratrol elevated at 24- and 48-hour time points presumably due to the hydrolytic 
reaction that reversed resveratrol monosulfate to trans-resveratrol as proposed by Walle T. et 
al [11,12]. Several additional small peaks were observed from the HPLC spectrum, but their 
chemical features were not further analyzed here because of their low amounts. 
 
trans-Resveratrol as the bioactive form in glioblastoma cells. Resveratrol monosulfate was 
prepared by incubating trans-resveratrol with the brain lysates for 2h, and then was analyzed 
by HPLC and LC/MS. It was also revealed that the monosulfate was the major metabolite and 
more than 1/2 of parent trans-resveratrol was biotransformed to resveratrol monosulfate. In 
difference with the situation of 100μM trans-resveratrol treatment, U251 cells treated by the 
same concentration of this mixture for 48 hours showed neither distinct growth suppression 
nor apoptosis signs (Figure 2).   
 
Figure  2.  Biotransformation and bioacitve form  evaluation  in  U251 cells  (A) The chemical 
structures of trans-resveratrol and resveratrol monosulfate; (B) Morphologic evaluation of U251 cells incubated 
with 100μM of trans-resveratrol and trans-resveratrol/resveratrol monosulfate mixture for 48 h by H&E staining 
(40X).   
 
No side-effect of resveratrol on normal rat brain cells. After 100μM resveratrol treatment, 
the  glioblastoma  U251  cells  exhibited  distinct  apoptosis  and  growth  inhibition,  but  the 
primarily  cultured  rat  glial  cells  and  neurons  kept  growth  and  showed  no  sign  of  cell Functional Foods in Health and Disease 2013; 3(5):146-153                    Page 151 of 153 
apoptosis and death, even incubated with 200μM resveratrol. Trypan blue staining revealed 
that the percentage of nonviable cells was 0.11%, 12.26%, 31.79%, 34.96%, and 52.73% in 
U251  cells,  but  0.17%,  1.09%,  0.95%,  1.61%,  and  1.99%  in  PBC  cells  after  100μM 
resveratrol treatment for 0, 12, 24, 36, and 48 hours, respectively. FCM analyses further 
demonstrated that  G1 and S fractions  were  37.7% and  25.7% in  normal U251 cells  and 
changed to 37.9% and 47.2% in the resveratrol-treated cells. In PBC cells, G1 and S fractions 
were 54.5% and 32.9% in normal cells and remained almost unchanged (53.7% and 35.0%) 
after resveratrol-treatment. The percentages of apoptotic cells in 100μM resveratrol-treated 
U251 and PBC cells were 24.3% and 1.1%, respectively. 
 
DISCUSSION: 
An  ideal  cancer  therapeutic  agent  should  have  minimal  cytotoxicity  to  normal  tissues, 
meanwhile, exerts crucial effects on cancer cells. Our results showed that resveratrol could 
induce glioblastoma U251 cells growth arrest and apoptosis, on the contrary resveratrol was 
insensitive to the PBC cells. Which suggested that resveratrol had no side effect on normal 
brain cells, but exerted significantly anti-glioblastoma bioactivity, furtherly, resveratrol could 
penetrate the blood-brain-barrier (unpublished data). Therefore, resveratrol would be an ideal 
cancer-therapy drug for clinical brain tumors therapy. 
trans-Resveratrol has been recognized as an ideal cancer preventive and therapeutic 
agent,  and  it  can  generate  one  or  more  metabolites  in  cells  [10,13].  However,  the 
pharmaceutical potentials of those metabolic products have not yet been well ascertained. 
Some  researchers  proposed  that  resveratrol  metabolite(s)  such  as  resveratrol  sulfates  or 
resveratrol glucuronides were the bioactive forms because of the low bioavailability of parent 
trans-resveratrol in vivo [11], while others considered that trans-resveratrol by itself was 
sufficient  to  cause  vital  cellular  and  molecular  consequences  in  the  treated  cancer  cells 
[14,15]. Apparently, determination of the bioactive form(s) of resveratrol in individual cell 
and cancer types becomes a fundamental issue for the successful application of resveratrol in 
clinical therapy.   
In  this  study,  it  was  found  that  the  metabolite  of  trans-resveratrol  was  mainly 
resveratrol  monosulfate,  and  rather  than  its  metabolite,  resveratrol  parent  form  exhibited 
anti-tumor activity in the human glioblastoma U251 cells. It is therefore demonstrated that 
the efficiency of metabolic reduction of trans-resveratrol is the major determinant of the fate 
of resveratrol-treated glioblastoma cells. These findings would be of translational values in 
exploring tumor-selective and personalized application of resveratrol in cancer prevention 
and treatment. 
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